ADC, Bispecifics and Kinase Blockers Steal the Spotlight at ESMO 2025 in Berlin
Pfizer, Merck, AstraZeneca and Bristol Myers Squibb were among the many biopharmas showing off novel cancer modalities at ESMO, with antibody-drug conjugates, bispecific antibodies and kinase inhibitors demonstrating encouraging efficacy and safety for various cancers.
ADC, Bispecifics and Kinase Blockers Steal the Spotlight at ESMO 2025 in Berlin Read More »
